Results 261 to 270 of about 15,828 (290)

Thrombocytopenia associated with c7E3 Fab (abciximab)

Annals of Hematology, 2002
Abciximab (c7E3 Fab) inhibits platelet aggregation and is used to prevent complications of percutaneous coronary intervention. Thrombocytopenia is an often-cited complication of abciximab. Pseudothrombocytopenia is due to ethylenediaminetetraacetate (EDTA)-activated platelet agglutination, resulting in a spuriously low platelet count. We have looked at
Anil Potti, Ralph Levitt, Apar Kishor Ganti, Debra A. Schell   +3 more
openaire   +3 more sources

Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

Journal of the American Medical Association (JAMA), 2005
CONTEXT The benefits of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) are still a matter of debate. OBJECTIVE To combine data from all randomized trials conducted with abciximab in STEMI.
G. De Luca, H. Suryapranata, G. Stone, D. Antoniucci, J. Tcheng, F. Neumann, F. Van de Werf, E. Antman, E. Topol   +8 more
semanticscholar   +1 more source

One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.

EuroIntervention, 2013
AIMS Thirty-day results of the double-blind, randomised Intracoronary Stenting and Antithrombotic Regimen -Rapid Early Action for Coronary Treatment (ISAR-REACT) 4 trial showed no difference in ischaemic complications and a reduction in bleeding by ...
S. Schulz, A. Kastrati, Miroslaw Ferenc, S. Massberg, K. A. Birkmeier, K. Laugwitz, S. Kufner, M. Gick, M. Dommasch, H. Schühlen, A. Schömig, P. Berger, J. Mehilli, F. Neumann   +13 more
semanticscholar   +1 more source

Abciximab: A New Antiaggregant Used in Angioplasty

Annals of Pharmacotherapy, 1996
OBJECTIVE: To review the scientific literature on the pharmacology and clinical uses of abciximab. DATA SOURCES: MEDLINE, Index Medicus, and bibliographic literature searches of English-language articles pertaining to abciximab, 7E3, m7E3, and c7E3 were performed.
Vincent F. Mauro, Tina B Genetta
openaire   +3 more sources

In vivo demonstration of an antithrombin effect of abciximab

The American Journal of Cardiology, 2000
Abciximab prolonged the activated clotting time (ACT) in a post hoc analysis from the Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications trial and an in vitro study has suggested an antithrombin effect of platelet glycoprotein IIb/IIIa inhibition. The purpose of this study was to evaluate the in vivo effects of
Jean-Pierre M. Geagea, Alvaro Domiguez, Jose Arias, Marian Hawkey, Srinivas Duvvuri, Ramy Doss, George Dangas, John A. Ambrose, John Coppola, Juan J. Badimon, K.Peter Rentrop, T. Elmquist   +11 more
openaire   +3 more sources

Extreme Thrombocytopenia Following Abciximab Therapy

Revista Española de Cardiología (English Edition), 2004
Antagonists of the glycoprotein IIb/IIIa receptor block the binding of fibrinogen and Von Willebrand factor to the platelet receptor. This effect can lead to bleeding and thrombocytopenia. We analyzed the incidence and clinical repercussions of severe thrombocytopenia (< 20 000 /microl) secondary to abciximab treatment in a prospective study of 375 ...
Miguel A. Prieto Palomino, Dolores M. Arias Garcia, Rocio M. Aragones Manzanares, José Luis Castillo Castro, Manuel Delgado Amaya, Juan A. Bullones Ramirez   +5 more
openaire   +3 more sources

Delayed immunologic thrombocytopenia induced by abciximab

Thrombosis and Haemostasis, 2004
SummaryAbciximab is an anti-GPIIb-IIIa drug widely used to prevent thrombotic complications during percutaneous coronary intervention. We now report on the immunologic origin of thrombocytopenia developing between 7 and 12 days after the onset of abciximab infusion.
Emilse Bermejo, Paquita Nurden, Pierre Coste, C. Jaïs, Alan T. Nurden, Lionel Leroux, Gisèle Clofent-Sanchez   +6 more
openaire   +3 more sources

Abciximab

Reactions weekly, 2020

semanticscholar   +1 more source

A Risk-Benefit Assessment of Abciximab in Angioplasty

Drug Safety, 1999
Advances in percutaneous coronary intervention (PCI) have allowed procedures to be performed on a variety of patients with a spectrum of challenging coronary anatomy. Abciximab has permitted further expansion and has made the procedure safer. Abciximab is a chimerised murine monoclonal antibody directed against the platelet glycoprotein (GP) IIb-IIIa ...
openaire   +3 more sources

Abciximab and Alveolar Hemorrhage

New England Journal of Medicine, 1998
Homayoun Khanlou, Shahriar Yazdanfar, Glenn Eiger   +2 more
openaire   +3 more sources